Nicotine Bitartrate Reduces Falls and Freezing of Gait in Parkinson Disease: A Reanalysis
Abraham Lieberman, Thurmon E Lockhart, Markey C Olson, Victoria A Smith Hussain, Christopher W Frames, Arshia Sadreddin, Margaret McCauley, Elizabeth Ludington, Abraham Lieberman, Thurmon E Lockhart, Markey C Olson, Victoria A Smith Hussain, Christopher W Frames, Arshia Sadreddin, Margaret McCauley, Elizabeth Ludington
Abstract
Objective: Determine if NC001, an oral formulation of nicotine that reduces levodopa-induced dyskinesias (LIDs) in MPTP-Parkinson monkeys, could reduce falls, freezing of gait (FOG), and LIDs in Parkinson disease (PD) patients. Methods: Previously collected data from a study analyzing the effects of NC001 on LIDs in PD patients were reanalyzed. Because indirect-acting cholinergic drugs are sometimes helpful in reducing falls, we hypothesized that NC001, a direct-acting cholinergic agonist, could reduce falls in PD. The original 12-center, double-blind, randomized trial enrolled 65 PD patients. NC001 or placebo was administered 4 times per day for 10 weeks, beginning at 4 mg/day and escalating to 24 mg/day. Assessments included the Unified Dyskinesia Rating Scale (UDysRS) and Parts II-III of the original Unified Parkinson's Disease Rating Scale (UPDRS). Results: Randomization (1:1) resulted in 35 patients on NC001 and 30 on placebo at baseline. Thirty and 27 patients, respectively, had data available for an intent-to-treat analysis. NC001 was safe and well-tolerated. After 10 weeks, NC001 patients (14/30) had a significant reduction in falls vs. placebo patients (3/27) (p = 0.0041) as assessed by UPDRS Part II. NC001 patients (12/30) also had significantly reduced FOG vs. placebo patients (4/27) (p = 0.0043). NC001 patients, compared with placebo patients, had a significant improvement (p = 0.01) in UDysRS ambulation subtest (40% vs. 3%, respectively). Although NC001 patients had a greater reduction in dyskinesias on the UDysRS than placebo patients (30% vs. 19%, respectively), this was not significant (p = 0.09). Conclusions: NC001 significantly improved two refractory symptoms of PD, falls and FOG. The reduction in falls and FOG is attributed to selective stimulation of nicotinic receptors. Clinical Trial Registration: Conducted under IND 105, 268, serial number 0000. ClinicalTrials.gov identifier NCT00957918.
Keywords: Dyskinesia; Parkinson disease; falls; freezing of gait; nicotine.
Figures
References
- Schaafsma JD, Balash Y, Gurevich T, Bartels AL, Hausdorff J, et al. . Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol. (2003) 10:391–8. 10.1046/j.1468-1331.2003.00611.x
- Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destee A, et al. . Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol. (2014) 71:884–90. 10.1001/jamaneurol.2014.753
- Shekelle P, Maglione M, Chang J. Evidence Report and Evidence-Based Recommendations: Falls Prevention Interventions in the Medicare Population. R. Corporation (2003).
- Pickering RM, Grimbergen YA, Rigney U, Ashburn A, Mazibrada G, et al. . A meta-analysis of six prospective studies of falling in Parkinson's disease. Mov Disord. (2007) 22:1892–900. 10.1002/mds.21598
- Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson's disease: a systematic review. Parkinsons Dis. (2013) 2013:906274. 10.1155/2013/906274
- Curtze C, Nutt JG, Carlson-Kuhta P, Mancini M, Horak F, et al. . Levodopa is a double-edged sword for balance and gait in people with Parkinson's disease. Mov Disord. (2015) 30:1361–70. 10.1002/mds.26269
- Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. (2001) 16:448–58. 10.1002/mds.1090
- Belluardo N, Mudo G, Blum M, Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res. (2000) 113:21–34. 10.1016/S0166-4328(00)00197-2
- Hukkanen J, Jacob P, III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. (2005) 57:79–115. 10.1124/pr.57.1.3
- Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, et al. . Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol. (2007) 62:588–96. 10.1002/ana.21203
- Quik M, Wonnacott S. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev. (2011) 63:938–66. 10.1124/pr.110.003269
- Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. (2008) 23:2398–403. 10.1002/mds.22341
- Fahn S, Elton R. Unified Parkinsons Disease Rating Scale (1987). Available online at: (accessed October 15, 2018).
- Bohnen NI, Muller ML, Koeppe RA, Studenski S, et al. . History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. (2009) 73:1670–76. 10.1212/WNL.0b013e3181c1ded6
- Perez-Lloret S, Barrantes FJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease. NPJ Parkinsons Dis. (2016) 2:16001. 10.1038/npjparkd.2016.1
- Chung KA, Lobb BM, Nutt JG, Horak F, et al. . Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. (2010) 75:1263–69. 10.1212/WNL.0b013e3181f6128c
- Henderson EJ, Lord SR, Brodie MA, Gaunt D, et al. . Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. (2016) 15:249–58. 10.1016/S1474-4422(15)00389-0
- West R, Ussher M, Evans M, Rashid M. Assessing DSM-IV nicotine withdrawal symptoms: a comparison and evaluation of five different scales. Psychopharmacology. (2006) 184:619–27. 10.1007/s00213-005-0216-z
- Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. (2011) 221:564–73. 10.1016/j.bbr.2009.12.048
- Nardone A, Schieppati M. Balance in Parkinson's disease under static and dynamic conditions. Mov Disord. (2006) 21:1515–20. 10.1002/mds.21015
- Rinne JO, Ma SY, Lee MS, Collan Y, et al. . Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat Disord. (2008) 14:553–7. 10.1016/j.parkreldis.2008.01.006
- Benarroch EE. Pedunculopontine nucleus: functional organization and clinical implications. Neurology. (2013) 80:1148–55. 10.1212/WNL.0b013e3182886a76
- Bensaid M, Michel PP, Clark SD, Hirsch E, et al. . Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease. Exp Neurol. (2016).275 (Pt 1): 209–19. 10.1016/j.expneurol.2015.11.004
- Collomb-Clerc A, Welter ML. Effects of deep brain stimulation on balance and gait in patients with Parkinson's disease: a systematic neurophysiological review. Neurophysiol Clin. (2015) 45:371–88. 10.1016/j.neucli.2015.07.001
- Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, et al. . Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest. (2010) 120:2745–54. 10.1172/JCI42642
- Thevathasan W, Debu B, Aziz T, Bloem BR, Blahak C, et al. . Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: a clinical review. Mov Disord. (2018) 33:10–20. 10.1002/mds.27098
- Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser R, et al. . Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord. (2017) 32:1701–9. 10.1002/mds.27131
Source: PubMed